To clarify the distinction between 'fecal microbiota product' and 'live biotherapeutic product' in microbiome-based therapeutics.
Key Findings:
Clear terminology helps clinicians distinguish between treatment modalities.
Fecal microbiota products and live biotherapeutic products may enhance treatment for Clostridioides difficile infection and multidrug-resistant infections.
Interpretation:
The distinction in terminology is crucial for effective communication and treatment strategies in microbiome therapies.
Limitations:
Conclusion:
Both fecal microbiota products and live biotherapeutic products are expected to remain valuable for treating infections and advancing scientific understanding.
